Journals / Viral Hepatitis Journal / 2017 / Cilt: 23 - Sayı: 1

Esrar ve Opiyat Bağımlılarında Hepatit B Virüsü, Hepatit C Virüsü ve HIV Enfeksiyonları Sıklığı

Frequency of Hepatitis B Virus, Hepatitis C Virus and HIV Infections in Cannabis and Opioid Addicts

Pages
26–29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Understanding of local status in HBV, HCV and HIV infections is crucial for developing prevention and geographical strategies for these infections

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: There are very few data about the epidemiology of hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV infections in drug addicts in Turkey, whereas several countries have a developed surveillance systems to monitor the spread of HBV, HCV and HIV infections in drug users.
📊
Key Findings & Data:The cannabis and opioid metabolites in urine samples of drug addicts were analyzed by cloned enzyme donor immunoassay.Results: This retrospective study was conducted on 276 individuals with a mean age of 28.89±10.49 years.
💡
Conclusion & Impact:Understanding of local status in HBV, HCV and HIV infections is crucial for developing prevention and geographical strategies for these infections
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: There are very few data about the epidemiology of hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV infections in drug addicts in Turkey, whereas several countries have a developed surveillance systems to monitor the spread of HBV, HCV and HIV infections in drug users. In this study, HBV, HCV and HIV prevalence in cannabis and opioid addicts were investigated.Materials and Methods: Hepatitis B surface antigen (HBsAg), antiHBs, anti-HCV and anti-HIV tests were analyzed by enzyme-linked immunosorbent assay. The cannabis and opioid metabolites in urine samples of drug addicts were analyzed by cloned enzyme donor immunoassay.Results: This retrospective study was conducted on 276 individuals with a mean age of 28.89±10.49 years. HBsAg, anti-HBs and anti-HCV prevalence in drug addicts was found to be 4%, 52.3% and 7.9%, respectively. In all the drug addicts, anti-HIV test was negative. Whereas the rate of HBsAg among cannabis users (8.8%) was higher than opioid (4.1%) and both cannabis and opioid users (1.4%), the difference was not statistically significant. Although antiHCV positivity among cannabis users was not detected, 6.4% of opioid users and 15.9% of both cannabis and opioid users were anti-HCV positive (p=0.009).Conclusion: This study showed that HCV infection among especially opioid users and both cannabis and opioid users was a problem. Understanding of local status in HBV, HCV and HIV infections is crucial for developing prevention and geographical strategies for these infections

Özet

Amaç: Bazı ülkelerde uyuşturucu kullanıcıları arasında hepatit B virüs (HBV), hepatit C virüs (HCV) ve HIV enfeksiyonlarının yayılmasını izlemek için gelişmiş bir sürveyans sistemi mevcutken, Türkiye'de uyuşturucu bağımlılarında HBV, HCV ve HIV enfeksiyonlarının epidemiyolojisi hakkında çok az veri mevcuttur. Bu çalışmanın amacı, esrar ve opiyat bağımlıları arasında HBV, HCV ve HIV sıklığını değerlendirmektir.Gereç ve Yöntemler: Hepatit B yüzey antijeni (HBsAg), anti-HBs, antiHCV ve anti-HIV testleri, Enzyme-Linked Immunosorbent Assay tekniği ile analiz edildi. Uyuşturucu bağımlılarının idrar örneklerinde esrar ve opiyat metabolitleri, klonlanmış enzim donör immünoassay tekniği ile analiz edildi.Bulgular: Bu retrospektif çalışma, yaş ortalaması 28,89±10,49 olan 276 olgu üzerinde gerçekleştirildi. Uyuşturucu bağımlılarında HBsAg, anti-HBs ve anti-HCV sıklığı sırasıyla %4, %52,3 ve %7,9 olarak tespit edildi. Tüm uyuşturucu bağımlılarında, anti-HIV testi negatifti. Esrar kullanıcıları arasında HBsAg sıklığı (%8,8), opiyat (%4,1) ve hem esrar hem de opiyat kullanıcılardan (%1,4) daha yüksek iken, bu fark istatistiksel olarak anlamlı değildi. Esrar kullanıcılarında antiHCV pozitifliği tespit edilmemesine rağmen, opiyat kullanıcılarının %6,4'ü hem esrar hem de opiyat kullanıcılarının %15,9'u anti-HCV pozitifti (p=0,009).Sonuç: Bu çalışma özellikle opiyat kullanıcıları ile hem esrar hem de opiyat kullanıcıları arasında HCV enfeksiyonunun sorun olduğunu göstermiştir. HBV, HCV ve HIV enfeksiyonlarında lokal durumun anlaşılması, bu enfeksiyonların önlenmesi ve coğrafi olarak stratejilerin geliştirilmesi için önemlidir

🔖

Cite This Article

KARABULUT, N., ÇATAK, Z. (2017). Esrar ve Opiyat Bağımlılarında Hepatit B Virüsü, Hepatit C Virüsü ve HIV Enfeksiyonları Sıklığı. Viral Hepatitis Journal, Cilt: 23 - Sayı: 1, 26–29. https://ajindex.com/articles/332672

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Karabulut N, Bulut Y, Telo S. Frequency of Hepatitis B and C Viruses, and HIV Among Drug Addicts in the Eastern Anatolia, Turkey. Jundishapur J Microbiol. 2015;8:e19698
  2. Administration SAAMHS. Cannabis [21.03.2016]. Available from:
  3. Administration SAAMHS. Opioids [21.03.2016]. Available from:
  4. Karabulut N. Prevalence of HBV, HCV and HIV in Inpatients of a Mental Health Hospital in Turkey, 2011-2013. Iran J Public Health. 2015;44:1026-1028
  5. Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HL, Hall HI, Lansky A, West BS, Friedman SR. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007. PLoS One. 2013;8:e64789
  6. Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stover H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ; International Network on Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57 (Suppl 2):S129-137
  7. Removille N, Origer A, Couffignal S, Vaillant M, Schmit JC, Lair ML. A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations. BMC Public Health. 2011;11:351
  8. Pharris A, Wiessing L, Sfetcu O, Hedrich D, Botescu A, Fotiou A, Nikolopoulos GK, Malliori M, Salminen M, Suk JE, Griffiths P, van de Laar MJ. Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill. 2011;16. pii: 20032
  9. Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, Antoniadou A, Lazanas M, Gargalianos P, Psychogiou M, Malliori M, Kremastinou J, Hatzakis A. HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. Euro Surveill. 2011;16. pii: 19962
  10. Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, Vlahov D, Strathdee SA, Hudson SM, Kerndt P, Des Jarlais D, Williams IT. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46:1852-1858
  11. Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Friedman SR, Monterroso E, Williams I, Garfein RS. Variability in the Incidence of Human Immunodeficiency Virus, Hepatitis B Virus, and He